Ger­many’s IQWiG finds first tu­mor-ag­nos­tic drug pro­vides no added ben­e­fit

Ger­many’s In­sti­tute for Qual­i­ty and Ef­fi­cien­cy in Health Care (IQWiG) this week said that Bay­er’s Vi­t­rakvi (larotrec­tinib), ap­proved in the EU last sum­mer, has not been proven to pro­vide an added ben­e­fit.

Vi­t­rakvi was the first med­i­cine to be ap­proved in the EU as a treat­ment for tu­mors with a spe­cif­ic mu­ta­tion, re­gard­less of where in the body the tu­mor orig­i­nat­ed. But the treat­ment’s safe­ty and ef­fi­ca­cy were eval­u­at­ed in three sin­gle-arm tri­als, and IQWiG took is­sue with the lack of com­para­tor arms in the tri­als.“

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER